Evaluation of the Antidiabetic Potential and Bioaccessibility of Propolis-Enriched Aronia Kombucha: An in Vitro Study

Why It Matters

The formulation boosts key phytochemicals linked to glucose‑regulating enzyme inhibition, positioning it as a promising low‑calorie, functional drink for diabetes risk reduction and the growing functional‑beverage market.

Key Takeaways

• Optimal formulation: 11.09 g L⁻¹ aronia tea, 1.42 % propolis.
• PAK retained ~34 % phenolics after simulated digestion.
• α‑Glucosidase inhibition rose to 42 % in propolis‑enriched kombucha.
• Chrysin levels increased >20‑fold with propolis addition.

Pulse Analysis

The functional‑beverage sector is racing to validate health claims with rigorous science, and kombucha remains a flagship product due to its probiotic and bioactive profile. By integrating aronia, a polyphenol‑rich chokeberry, and propolis, a bee‑derived flavonoid source, the study leverages complementary phytochemical matrices. The response surface optimization not only maximizes total phenolic content but also fine‑tunes flavonoid diversity, delivering compounds such as chrysin and quercetin that are known to modulate carbohydrate‑digesting enzymes. This synergy translates into measurable enzyme inhibition, a key mechanistic pathway for attenuating post‑prandial glucose spikes.

From a market perspective, consumers increasingly seek beverages that combine taste with clinically relevant benefits. The demonstrated 42 % α‑glucosidase and 44.7 % α‑amylase inhibition positions propolis‑enriched aronia kombucha as a candidate for “functional‑food‑as‑medicine” positioning, especially for pre‑diabetic or health‑conscious segments. Moreover, the study’s simulated digestion data show that roughly one‑third of phenolics survive gastrointestinal transit, suggesting a realistic bioactive dose reaches the small intestine where glucose absorption occurs. Such bioaccessibility evidence strengthens regulatory dossiers and can support health‑claim substantiation under FDA guidance.

Future research must move beyond in‑vitro assays to human trials that assess glycemic response, gut‑microbiome interactions, and long‑term safety. Shelf‑life stability, sensory acceptance, and scalable production of propolis‑enriched kombucha will also dictate commercial viability. Nonetheless, the current findings provide a compelling proof‑of‑concept that targeted enrichment of kombucha can elevate its antidiabetic potential, aligning product innovation with the growing demand for evidence‑based functional drinks.